Hungary: A New Model of Care
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company.
LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. To realise our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs.
LEO Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide and generates approximately USD 1.2 billion in annual turnover. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.
2015 was the year LEO Pharma embarked on our ‘Helping SARAH – LEO towards 2020’ journey – a new strategy which was launched in December 2014. With the ambitious aspiration to help more than 100 million people in 2020, LEO Pharma has committed itself to looking at new and innovative solutions and keeping engaging in partnerships to reach its goal. LEO Pharma wants to offer solutions in all aspects of life for people living with skin diseases, to assist them in taking control of their condition and improve their quality of life. We have set out on a mission to help people achieve healthy skin; in addition to our products, we offer patients a growing list of solutions and services. As part of our 2020 strategy, we have established LEO Innovation Lab, a separate business unit operating independently outside our traditional business. LEO Innovation Lab works to improve the well-being of people living with psoriasis by developing digital solutions and services. Generic competition is today a market condition when running a pharmaceutical business with strong products and solutions, and 2015 was no exception. This year we upheld our patents for Daivobet® Ointment in court rulings in the UK and Canada. The result for 2015 is considered satisfactory
Contact
LEO Pharma A/S Hungarian Commercial Representative Office
Regus Obuda Gate
Arpad fejedelem utja 26-28., 5th floor
1023 Budapest
Hungary
Tel. (+36) 1 888 0525
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have…
Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence…
While pharmaceutical products and healthcare financing dominate the majority of discussions surrounding the improvement of health outcomes, health literacy still remains a core issue that, if left unaddressed, may vary…
Preventive healthcare and health literacy are core issues in Hungary that, if left unaddressed, may hinder the country’s ability to push its health agenda forward and create a more sustainable…
Smaller pharma companies in Hungary are looking to new unconventional methods of OTC promotion to sidestep the country’s somewhat restrictive reimbursement scheme and compete with major players in the market. Especially in…
The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges…
LEO Pharma Hungary’s Andrea Bondár demonstrates the significance of adopting non-traditional methods of promotional activities, and defines how a true intent on understanding the psyche of patients suffering from chronic…
Anita Ordog, GM of Angelini Hungary, discusses the affiliate’s history in the country, their expanding OTC and specialty products portfolio, targeted marketing and sales strategies, and Angelini’s challenging entrance into…
Dr. Lívia Ilku, director of Hungary’s main domestic pharmaceutical manufacturers’ association (MAGYOSZ), describes the current priorities of its member companies and the key factors for success in Hungary; specifically innovation…
Prof. Dr. István Vályi-Nagy, Director General of the United St. Istvan and St. Laszlo Hospitals, shares his insights on running one of the largest hospitals in Hungary and the challenges…
The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic…
See our Cookie Privacy Policy Here
